Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Philips buys Northern...

    Philips buys Northern Irish medical imaging company

    Written by savita thakur thakur Published On 2016-06-22T15:15:23+05:30  |  Updated On 22 Jun 2016 3:15 PM IST

    Philips (PHG.AS), the Dutch medical technology company, said it had purchased PathXL, a Belfast-based digital imaging analysis and software company.


    Terms were not disclosed.


    Philips CEO Frans van Houten said in a telephone interview that its digital pathology business was "doubling every year." A company spokesman said its digital pathology sales would pass "several tens of millions" of euros in sales this year, including the acquisition.


    In digital pathology, tissue samples are scanned and stored in computer files so they can be summoned by doctors for instant, computer assisted analysis or repeatedly reviewed.


    "The computer can do a much better job than the human eye, as it is much more systematic in analyzing tissues," Van Houten said. "We're acquiring a company that has deep clinical knowledge and technology to analyze cancerous cells."


    The PathXL acquisition comes as Philips seeks to complete its decade-long transition from an electronics company to a vendor of cloud-connected medical devices and systems used by both hospitals and consumers.


    Last month, it sold a 25 percent stake in Philips Lighting, its last remaining non-health operation, in part to raise money for investments such as the PathXL deal.


    Separately, Philips said it had struck a deal with Visiopharm to license the Danish company's breast cancer software analysis for use on Philips' digital pathology platform.


    That partnership "will widen the capabilities of our pathology business and make it even more attractive for pathologists to adopt," Van Houten said.

    breast cancercancerDanishFrans van HoutenLicencesmedical imagingPathXLPhilips
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok